AlphaCentric Advisors’s Design Therapeutics DSGN Stock Holding History
Bought
Maintained
Sold
Other funds holding DSGN
AlphaCentric Advisors's DSGN Position: Q3 2026 in Review
AlphaCentric Advisors increased its Design Therapeutics (DSGN) stake by 4.5% in Q3 2026, buying an estimated $13.4K and bringing the position to 22,505 shares worth $283K. The position accounts for 0.25% of the portfolio, ranked #119.
AlphaCentric Advisors first reported a position in DSGN in Q4 2025 and has held it in 4 quarters since. The position peaked at $312K in Q2 2026. 94 funds tracked by Wall St. Rank hold DSGN as of Q3 2026.
- AlphaCentric Advisors held 22,505 shares of Design Therapeutics worth $283K as of Q3 2026.
- AlphaCentric Advisors bought 968 Design Therapeutics shares in Q3 2026, an estimated $13.4K.
- Design Therapeutics made up 0.25% of AlphaCentric Advisors's portfolio in Q3 2026, its #119 holding.
- AlphaCentric Advisors first reported a position in Design Therapeutics in Q4 2025 and has held it in 4 quarters since.
- AlphaCentric Advisors's Design Therapeutics position peaked at $312K in Q2 2026.
- 94 funds tracked by Wall St. Rank held Design Therapeutics as of Q3 2026.
Based on AlphaCentric Advisors's 13F filing for Q3 2026, filed 3 Nov 2026.